We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > OncoArendi Therapeutics

News List

OncoArendi Therapeutics Announces Selection of Its Second Clinical Development Candidate: OATD-02 Fo b3cnewswire
June 27, 2017
OncoArendi Therapeutics SA announced that it has selected OATD‑02 as its clinical development candidate for cancer immunotherapy. Submission of the Company's second Investigational New Drug ("IND") application is expected by the third quarter of 2018.
OncoArendi Therapeutics Announces Selection of Its Second Clinical Development Candidate: OATD-02 Fo b3cnewswire
June 23, 2017
OncoArendi Therapeutics Announces Selection of Its Second Clinical Development Candidate: OATD-02 For the Treatment of Multiple Cancers